Lamivudine (3TC)
Sponsors
French National Agency for Research on AIDS and Viral Hepatitis, Kirby Institute, Boehringer Ingelheim, ViiV Healthcare, Instituto de Investigación Hospital Universitario La Paz
Conditions
AIDSAicardi-Goutières SyndromeHIV InfectionsHIV-1-infectionHealthyInfection, Human Immunodeficiency Virus
Phase 1
Phase 2
Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)
CompletedNCT00122538
Start: 2006-02-28End: 2009-05-31Updated: 2011-12-05
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir
CompletedNCT02249130
Start: 1999-03-31Updated: 2014-09-25
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.
NCT03539224
Start: 2017-11-02End: 2021-07-31Updated: 2020-07-07
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
CompletedNCT04731103
Start: 2022-08-24End: 2024-03-11Updated: 2024-05-09
Phase 3
Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)
CompletedNCT00158405
Start: 2002-12-31End: 2006-12-31Updated: 2008-12-30
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
CompletedNCT00640263
Start: 2009-12-31End: 2014-02-28Target: 1500Updated: 2014-04-14
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
CompletedNCT02181933
Start: 1999-04-30Updated: 2014-07-14
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
CompletedNCT02831764
Start: 2016-07-18End: 2022-06-29Updated: 2023-12-07
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
CompletedNCT02831673
Start: 2016-07-21End: 2022-08-15Updated: 2023-08-24